Janssen, “We’ll start Phase II clinical trial of new obesity & diabetes biologic”

The global Phase II clinical trial for HM12525A, a Hanmi Pharm’s new obesity & diabetes biologic being developed by Janssen, a global pharmaceutical company, will start soon. The clinical trial will evaluate efficacy of ‘HM12525A’ on 440 severe obesity patients.

ClinicalTrials.gov, a U.S. clinical study information website, had an update about the Janssen’s official registration of the clinica...